AstraZeneca: Phase 1 study completed, 10 enrolled (Kidney Failure)
AstraZeneca: Phase 1 study completed, 10 enrolled (Kidney Failure). Its enrollment of 10 is below the median of 80 (3rd percentile). Dated 16 days ago, it is in the active follow-up window. Score 50/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 10 · 3th percentile of 8,879 ClinicalTrialStartPulse records · 0.1x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related US ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | AstraZeneca |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin |
| NCT ID | NCT07754331 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Kidney Failure |
| Intervention types | drug |
| Target enrollment | 10 |
| Site countries | United States |
| Posted | 2026-08-10 |
| Planned start | 2026-08-06 |
| Event | Completed |
| Event date | 2026-10-06 |
| Last update posted | 2026-10-20 |
| enrollment percentile | 3th of 8,879 (median 80, 0.1x median) |
| Peer records CSV (500 US records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch AstraZeneca
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of US records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock AstraZeneca + 500 US peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-20
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (US first): Sanofi · Pfizer · National Institute of Arthritis and Musculoskeletal and Skin · Apple Inc. · National Cancer Institute (NCI) · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: AstraZeneca and 2,512 US peers
- US ClinicalTrialStartPulse records like this one: 2,512
- AstraZeneca's enrollment: 3rd percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every US peer: $502,400 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
50 / 100 Score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
What is the ClinicalTrialStartPulse record for AstraZeneca?
AstraZeneca's Phase 1 study (NCT07754331) in Kidney Failure, first posted 2026-08-10: completed (2026-10-06), in an update posted 2026-10-20.
How does AstraZeneca compare to other ClinicalTrialStartPulse records?
Its enrollment of 10 is below the median (3th percentile); smaller records often move faster and face less competition. It is 16 days old, still within a typical 45-day follow-up window.
AstraZeneca vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| AstraZeneca | US | 10 | 3rd | 2026-10-20 |
| Janssen Research & Development, LLC | US | 144 | 69th | 2026-11-03 |
| Genentech, Inc. | US | 165 | 72nd | 2026-11-03 |
| Hoffmann-La Roche | US | 180 | 74th | 2026-11-03 |
Related records
- Hoffmann-La Roche
- MacroGenics
- Mabsoft Therapeutics (Shanghai) Co., Ltd.
- Sutro Biopharma, Inc.
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Genentech, Inc.
ClinicalTrialStartPulse: Phase 1 ClinicalTrialStartPulse: United States sites
How to monitor AstraZeneca and peer phase 1 records
Get new ClinicalTrialStartPulse records like AstraZeneca by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.